Interesting – looks like it doesn’t email us unless we are watchers.

 

So to clarify – we should always look for the TSC Jira tracker to see what date it was extended to?

 

Linda

 

From: Lynn Laakso <lynn@hl7.org>
Sent: Wednesday, November 30, 2022 1:32 PM
To: Michaelsen, Linda J <linda.michaelsen@optum.com>
Cc: cdamg@lists.hl7.org
Subject: RE: Publication Extension Request

 

I extended it to 11/19/2024 as noted in my comment which included my @ mention to you and Lisa on https://jira.hl7.org/browse/TSC-306

 

Thanks,

Lynn

Lynn @ HL7 dot org, (313) 444 – two 449

 

HL7 has moved to a new Association Management System (AMS), Fonteva. 

Learn more about it or view FAQs.

 

HL7 FHIR Connectathon
January 14 - 15, 2023, Henderson NV - Register Now!!


January Working Group Meeting
January 16 - 20, 2023, Henderson, NV - Register Now!!

 

From: Michaelsen, Linda J <linda.michaelsen@optum.com>
Sent: Wednesday, November 30, 2022 2:28 PM
To: Lynn Laakso <lynn@hl7.org>
Cc: cdamg@lists.hl7.org
Subject: Publication Extension Request

 

Hey Lynn

 

We have a question, when am extension is requested and approved, what date is the extension based on?  So for example, I am looking at this one, 2022-11 CDA HAI LTCF Publication Extension Request - Public Health - Confluence (hl7.org)

 

Original expiration date was 11/19/2022.  It was requested on 11/10/2022 and approved on 11/21/2022 by TSC.

 

We maintain this in CMG product inventory so wanted to ensure we were doing it correctly.

 

ThanQ,

LInda

 

Linda Michaelsen (she/her)

Director, Healthcare Interoperability Standards [Provider Engineering | Optum Technology

 

O 1-612-632-6664

M 1-314-604-8440

linda.michaelsen@optum.com

 

16958 Westridge Oaks Dr

Wildwood MO  63040

 

 

A picture containing text, clipart Description automatically generated

 


This e-mail, including attachments, may include confidential and/or
proprietary information, and may be used only by the person or entity
to which it is addressed. If the reader of this e-mail is not the intended
recipient or intended recipient’s authorized agent, the reader is hereby
notified that any dissemination, distribution or copying of this e-mail is
prohibited. If you have received this e-mail in error, please notify the
sender by replying to this message and delete this e-mail immediately.


This e-mail, including attachments, may include confidential and/or
proprietary information, and may be used only by the person or entity
to which it is addressed. If the reader of this e-mail is not the intended
recipient or intended recipient’s authorized agent, the reader is hereby
notified that any dissemination, distribution or copying of this e-mail is
prohibited. If you have received this e-mail in error, please notify the
sender by replying to this message and delete this e-mail immediately.